Analyzing...
Loading company...
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹637 Cr revenue.
COGS 23.8%, employees 22.2%.
“top line for the quarter stood”
“Instead of 2% on EBITDA impact from tariffs, I think it will be around 1% or so. This is the worst case scenario.”
“We remain optimistic. Our focus on operational excellence helped us maintain steady momentum towards the full year guidance.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 10.3%▼ | 10.5% |
| ROCE | 13.8% | 13.8% |
| Net Margin | 20.4%▲ | 8.7% |
| EBITDA Margin | 34.7%▲ | 16.0% |
| Debt To Equity | 0.01x▼ | 0.21x |
| Rev Growth 3yr | 7.7%▲ | 5.8% |
| EPS Growth 3yr | 3.1%▼ | 3.6% |
Historical valuation data not available.
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹710 Cr +11.4% | ₹637 Cr +2.1% | ₹624 Cr +15.4% | ₹541 Cr +2.1% | ₹529 Cr +5.5% | ₹502 Cr +13.0% | ₹444 Cr +5.8% | ₹420 Cr |
| Other Income | ₹36 Cr +10.0% | ₹33 Cr -9.9% | ₹37 Cr +44.0% | ₹25 Cr +296.5% | ₹6 Cr -27.4% | ₹9 Cr +56.8% | ₹6 Cr +12.1% | ₹5 Cr |
| Total Income | ₹746 Cr +11.3% | ₹670 Cr +1.4% | ₹661 Cr +16.7% | ₹566 Cr +5.7% | ₹536 Cr +4.9% | ₹511 Cr +13.6% | ₹450 Cr +5.9% | ₹425 Cr |
| COGS | ₹182 Cr +19.9% | ₹152 Cr +5.0% | ₹145 Cr +9.7% | ₹132 Cr +20.1% | ₹110 Cr +10.8% | ₹99 Cr +22.4% | ₹81 Cr +4.8% | ₹77 Cr |
| ₹541 Cr +12.1% | ₹483 Cr +5.5% | ₹458 Cr +8.5% | ₹422 Cr +15.6% | ₹365 Cr +21.5% | ₹300 Cr +11.0% | ₹270 Cr +3.0% | ₹263 Cr | |
| Profit Before Tax | ₹216 Cr +15.4% | ₹187 Cr -0.2% | ₹188 Cr +33.8% | ₹140 Cr -17.9% | ₹171 Cr -18.7% | ₹210 Cr +17.4% | ₹179 Cr +10.6% | ₹162 Cr |
| Exceptional Items | ₹11 Cr | ₹0.00 Cr +100.0% | (₹15 Cr) -272.5% | (₹4 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
| ₹61 Cr +14.5% | ₹53 Cr +5.0% | ₹51 Cr +39.3% | ₹37 Cr -22.7% | ₹47 Cr -19.8% | ₹59 Cr +27.8% | ₹46 Cr +0.1% | ₹46 Cr | |
| Net Profit | ₹155 Cr +15.8% | ₹134 Cr -2.2% | ₹137 Cr +31.9% | ₹104 Cr -16.1% | ₹124 Cr -18.3% | ₹151 Cr +13.8% | ₹133 Cr +14.8% | ₹116 Cr |
| Profit (Owners) | ₹152 Cr +16.1% | ₹131 Cr -1.6% | ₹133 Cr +26.2% | ₹106 Cr -11.7% | ₹120 Cr -18.2% | ₹146 Cr +13.1% | ₹129 Cr +16.4% | ₹111 Cr |
| Minority Interest | ₹3 Cr -0.5% | ₹3 Cr -21.6% | ₹4 Cr ↑ Recovery | (₹2 Cr) ↓ Decline | ₹4 Cr -19.9% | ₹5 Cr +40.2% | ₹4 Cr -22.5% | ₹5 Cr |
| Other Comprehensive Income | ₹48 Cr +152.6% | ₹19 Cr +103.5% | ₹9 Cr -83.1% | ₹55 Cr +230.7% | ₹17 Cr ↑ Recovery | (₹10 Cr) ↓ Decline | ₹39 Cr +183.2% | ₹14 Cr |
| EPS | ₹13.61 | ₹11.72 | ₹11.92 | ₹9.45 | ₹10.70 | ₹13.09 | ₹11.58 | ₹9.95 |
| Diluted Shares | ₹11 Cr | ₹11 Cr | ₹11 Cr | ₹11 Cr | ₹11 Cr | ₹11 Cr | ₹11 Cr | ₹11 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Chandrakumar Laxminarayan Rathi has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers...
Advanced Enzyme Technologies Limited has informed the Exchange regarding Change in Director(s) of the company.
Advanced Enzyme Technologies Limited has informed the Exchange about Transcript
Advanced Enzyme Technologies Limited has informed the Exchange about Link of Recording
Advanced Enzyme Technologies Limited has informed the Exchange about Copy of Newspaper Publication
Advanced Enzyme Technologies Limited has informed the Exchange regarding a press release dated May 09, 2026, titled "Quarterly Earnings Release dated May 09, 2026".
Advanced Enzyme Technologies Limited has informed the Exchange about Investor Presentation
Advanced Enzyme Technologies Limited has informed the Exchange regarding Allotment of 49350 Shares.
Advanced Enzyme Technologies Limited has informed the Exchange regarding Change in Auditors of the company.
Advanced Enzyme Technologies Limited has informed the Exchange regarding Appointment of Mr. Pradip Bhailal Shah as Independent Director of the company w.e.f. Jun 12, 2026.
Advanced Enzyme Technologies Limited has informed the Exchange regarding Appointment of Mr Mukund Madhusudan Kabra as Executive Director of the company w.e.f. April 01, 2027.
The Board has decided to defer the declaration of an interim dividend. While the Company continues to maintain a healthy financial position and robust liquidity, the Board intends to preserve capital ...
Advanced Enzyme Technologies Limited has informed the Exchange that Board of Directors at its meeting held on May 09, 2026, recommended Final Dividend of Rs. 1.35 per equity share.
Advanced Enzyme Technologies Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
Advanced Enzyme Technologies Limited has informed the Exchange regarding Resignation of Dipak Roda as Other of the company w.e.f. April 09, 2026.